Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.

Somayya NooriChristie P M VerkleijMarina ZajecPieter LangerhorstPatricia W C BosmanYolanda B de RijkeSonja ZweegmanMartijn VanDuijnTheo LuiderNiels W C J van de DonkJoannes F M Jacobs

Published in: Clinical chemistry and laboratory medicine (2021)

Daratumumab and nivolumab interfere with electrophoretic M-protein diagnostics. However, the M-protein can be distinguished from both t-mAbs by use of a double hydrashift assay. The MS-MRD assay provides an alternative method that allows sensitive and simultaneous quantitative monitoring of both the M-protein and t-mAbs.

Keyphrases

multiple myeloma
protein protein
amino acid
binding protein
multiple sclerosis
high throughput
small molecule
single cell